Anti-Mouse/Human CD273 (PD-L2) (Clone 3.2.B8) - Purified in vivo GOLD™ Functional Grade - 25 mg

B, FC, in vivo, WB

PD-L2

Next Day 2 - 8°C

PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.

Binds to PD-1 and alternative receptor;

PD-1, uncharacterized receptor

Clone 3.2.B8 recognizes an epitope on mouse/human PD-L2 and has been shown to bind to both mouse and human PD-L2 equally well

≥ 5.0 mg/ml

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Made in PD-L2 knockout mouse fusion partner X63-Ag8.653 myeloma cells

PD-L2, B7-DC, CD273, PDL2, B7DC, 3.2, mouse B7-DC, PD-L2, PDL2, B7DC, B7-DC, bA574F11.2, Btdc, Butyrophilin B7-DC, Butyrophilin-like Protein, CD273 antigen, CD273, MGC142240, PDCD1L2MGC142238, PDCD1LG2, PDL2, PD-L2, PDL2B7DC, PD-L2PDCD1 ligand 2, programmed cell death 1 ligand 2, Programmed death ligand 2, B7 dendritic cell molecule, mouse B7-DC, mouse B7DC, bA574F11.2, Btdc, Butyrophilin B7-DC, butyrophilin-like protein, CD273, PDL2, PDCD1 ligand 2, PDCD1L2, mouse PDL2, Programmed cell death 1 ligand 2, programmed death ligand 2, B7-DC, B7DC, bA574F11.2, Btdc, CD273, F730015O22Rik, mouse PD-L2, PDCD1L2, PDCD1LG2, PDL2